A Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in China
CLM-tree datab
Database of Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in China
1 other identifier
observational
1,000
1 country
2
Brief Summary
This is a retrospective and prospective study planned to include NSCLC patients with Leptomeningeal metastasis (LM) and treated with antitumor therapy after 2018, from multiple centers such as the First Affiliated Hospital of Guangzhou Medical University, Guangdong Sanjiu Brain Hospital, etc., aiming to establish a database related to the treatment strategies of LM patients, and to evaluate the efficacy (eg. Overall Survival/Time to Failure) and safety of different treatment strategies of LM patients, etc., as well as the significance of concomitant testing in LM patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2024
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2024
CompletedFirst Submitted
Initial submission to the registry
November 27, 2024
CompletedFirst Posted
Study publicly available on registry
December 5, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2028
April 27, 2025
April 1, 2025
4.3 years
November 27, 2024
April 24, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Overall survival(OS)
6 years
Secondary Outcomes (3)
Time to failure(TTF)
6 years
Change in cerebrospinal fluid and metabolic markers during treatment
6 years
Safety during actual clinical treatment
6 years
Interventions
This is a retrospective and observational study. Not Applicable
Eligibility Criteria
non-small cell lung cancer patients with Leptomeningeal metastases
You may qualify if:
- non-small cell lung cancer patients with Leptomeningeal metastases diagnosed after January 2018;
- Patients who underwent antitumor therapy after diagnosis of LM.
You may not qualify if:
- Patients with small cell lung cancer components;
- complicated with tumors other than non-small cell lung cancer.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Guangdong Sanjiu Brain Hospital
Guangzhou, Guangdong, 510000, China
the First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510120, China
Biospecimen
Blood and cerebrospinal fluid
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief Physician
Study Record Dates
First Submitted
November 27, 2024
First Posted
December 5, 2024
Study Start
September 1, 2024
Primary Completion (Estimated)
December 31, 2028
Study Completion (Estimated)
December 31, 2028
Last Updated
April 27, 2025
Record last verified: 2025-04